ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2756

Effect of Baseline and Change in Effusion-Synovitis on Cartilage Damage over 18 Months in Patients with Osteoarthritis and Meniscal Tear

Lindsey A. MacFarlane1, Heidi Y. Yang2, Jamie E. Collins3, Mohamed Jarraya4, Ali Guermazi5, Lisa A. Mandl6, Elena Losina3 and Jeffrey N. Katz7, 1Rheumatology, Brigham & Women's Hospital, Boston, MA, 2Orthopaedic and Arthritis Center for Outcomes Research, Brigham & Women's Hospital, Boston, MA, 3Orthopaedic and Arthritis Center for Outcomes Research, Department of Orthopedic Surgery, Brigham & Women's Hospital, Boston, MA, 4Musculoskeletal Radiology, Boston University School of Medicine, Boston, MA, 5Boston University School of Medicine, Boston, MA, 6Department of Rheumatology, Hospital for Special Surgery, New York, NY, 7Rheumatology, Immunology, and Allergy, Brigham & Women's Hospital, Boston, MA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: meniscus, osteoarthritis and synovitis

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 7, 2017

Title: Plenary Session III

Session Type: ACR Plenary Session

Session Time: 11:00AM-12:30PM

Background/Purpose:

Synovitis is a common feature in meniscal tear (MT) and osteoarthritis (OA). Synovitis has been associated with progression of cartilage damage in persons with OA, as has arthroscopic partial meniscectomy (APM), a frequent treatment for MT. It is unknown whether the presence or the persistence of effusion-synovitis is associated with changes in cartilage damage in patients with concurrent MT and OA.

Methods:

We used data from the Meniscal Tear in Osteoarthritis Research (MeTeOR) Trial of APM vs. physiotherapy (PT). Subjects were ≥45 years old, had MT on MRI, OA on MRI or radiograph, and knee symptoms. Subjects crossing-over between treatment groups or without both baseline and 18mo MRI were excluded. MRIs were read using the MRI OA Knee Score (MOAKS). Baseline effusion-synovitis was dichotomized as none/mild (0) and moderate/severe (1). Change in effusion-synovitis over 18mo was categorized as never developed (0 at baseline, 0 at 18mo), intermittent (1 at only 1 time point), and persistent (1 at baseline, 1 at 18mo). Change in cartilage damage over 18mo was examined in 14 subregions and assessed by a) number of subregions with worsening (subregions grade ≥1 at baseline with increased surface area affected by full thickness loss) and b) number of additional subregions affected (subregions grade 0 at baseline with new full thickness loss). Both outcomes were specified as binary (0 regions vs. 1+). We used logistic regression to investigate the associations between a) baseline effusion and b) change in effusion on both cartilage damage outcomes over 18mo in 4 individual models – with adjustment for differences in treatment (APM vs. PT), sex, BMI, and baseline cartilage damage.

Results:

We analyzed 174 knees (1/person), 102 had APM and 72 PT. Moderate/severe effusion was observed in 48% patients at baseline and 29% at 18mo. Fifty-six percent of subjects had subregions with worsening and 45% had additional subregions affected. Over 18mo, 44% subjects never developed effusion, 35% had intermittent effusion, and 21% had persistent effusion. Overall participants were 59% female, 58 years old, with a BMI of 30 kg/m2. Compared to subjects who never developed effusion, those with intermittent effusion had 2.6-fold (95% CI 1.2, 5.5) greater odds of worsening cartilage damage, while those with persistent effusion had 4.5-fold (95% CI 1.6, 12.8) greater odds. Similar results were obtained for analyses of baseline effusion and number of additional subregions affected (Table).

Conclusion:

Effusion-synovitis status at baseline and 18mo was associated with worsening of cartilage damage at 18mo in patients with MT and OA, independent of study treatment. The risk of cartilage damage was greater in those with persistent effusion than in those with intermittent effusion. If confirmed in other studies, these findings would support research on the structural effects of interventions to reduce effusion in this population.

Table: Odds ratios from logistic regression of A) Baseline and B) Change in Effusion-Synovitis on Cartilage Damage over 18 months

A. Baseline Effusion-synovitis

N

1+ subregion with worsening cartilage damage*

Odds Ratio (95% CI)

1+ additional subregion affected by cartilage damage*

Odds Ratio (95% CI)

Baseline Effusion-synovitis

None/mild

92

REF

REF

Moderate/severe

84

2.9 (1.4, 5.9)

2.8 (1.4, 5.5)

B. 18 Month Change in Effusion-synovitis

N

1+ subregion with worsening cartilage damage*

Odds Ratio (95% CI)

1+ additional subregion affected by cartilage damage*

Odds Ratio (95% CI)

Change in Effusion-synovitis

Never Developed

77

REF

REF

Intermittent

61

2.6 (1.2, 5.5)

2.2 (1.1, 4.7)

Persistent

36

4.5 (1.6, 12.8)

4.0 (1.5, 10.3)

*all models adjusted for treatment (APM vs PT), sex, BMI and baseline cartilage damage

Change in effusion-synovitis: never developed (none/mild at baseline and 18mo), intermittent (mod/severe at only 1 time point), persistent (mod/severe at baseline and 18mo)


Disclosure: L. A. MacFarlane, None; H. Y. Yang, None; J. E. Collins, None; M. Jarraya, None; A. Guermazi, BICL, LLC, 1,MerckSerono, TissueGene, OrthoTrophix, AstraZeneca and Genzyme, 5; L. A. Mandl, Boehringer Ingelheim, 2,American College of Physicians, 3,Up To Date, 7; E. Losina, None; J. N. Katz, None.

To cite this abstract in AMA style:

MacFarlane LA, Yang HY, Collins JE, Jarraya M, Guermazi A, Mandl LA, Losina E, Katz JN. Effect of Baseline and Change in Effusion-Synovitis on Cartilage Damage over 18 Months in Patients with Osteoarthritis and Meniscal Tear [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/effect-of-baseline-and-change-in-effusion-synovitis-on-cartilage-damage-over-18-months-in-patients-with-osteoarthritis-and-meniscal-tear/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/effect-of-baseline-and-change-in-effusion-synovitis-on-cartilage-damage-over-18-months-in-patients-with-osteoarthritis-and-meniscal-tear/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology